De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Xbrane Biopharma Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Xbrane Biopharma heeft een totaal eigen vermogen van SEK304.5M en een totale schuld van SEK119.8M, wat de schuld-eigenvermogensverhouding op 39.3% brengt. De totale activa en totale passiva bedragen respectievelijk SEK837.2M en SEK532.6M.

Belangrijke informatie

39.3%

Verhouding schuld/eigen vermogen

SEK 119.82m

Schuld

Rente dekkingsratio	n/a
Contant	SEK 72.84m
Aandelen	SEK 304.54m
Totaal verplichtingen	SEK 532.65m
Totaal activa	SEK 837.19m

Recente financiële gezondheidsupdates

Recent updates

Even With A 30% Surge, Cautious Investors Are Not Rewarding Xbrane Biopharma AB (publ)'s (STO:XBRANE) Performance Completely

Sep 30

Market Cool On Xbrane Biopharma AB (publ)'s (STO:XBRANE) Revenues Pushing Shares 34% Lower

Aug 05

Market Might Still Lack Some Conviction On Xbrane Biopharma AB (publ) (STO:XBRANE) Even After 32% Share Price Boost

Jun 21

Is Xbrane Biopharma (STO:XBRANE) In A Good Position To Deliver On Growth Plans?

Jun 04

We Think Xbrane Biopharma (STO:XBRANE) Needs To Drive Business Growth Carefully

Nov 05

Market Sentiment Around Loss-Making Xbrane Biopharma AB (publ) (STO:XBRANE)

Mar 24

Xbrane Biopharma AB (publ) (STO:XBRANE) Insiders Increased Their Holdings

Mar 02

Xbrane Biopharma AB (publ)'s (STO:XBRANE) Intrinsic Value Is Potentially 28% Above Its Share Price

Feb 10

We Think Xbrane Biopharma (STO:XBRANE) Can Afford To Drive Business Growth

Jan 12

What Kind Of Investors Own Most Of Xbrane Biopharma AB (publ) (STO:XBRANE)?

Dec 16

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( SEK652.0M ) XBRANE } overtreffen de korte termijn passiva ( SEK407.5M ).

Langlopende schulden: De kortetermijnactiva XBRANE ( SEK652.0M ) overtreffen de langetermijnschulden ( SEK125.2M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 15.4% ) XBRANE wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van XBRANE is de afgelopen 5 jaar gestegen van 0.03% naar 39.3%.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: XBRANE heeft minder dan een jaar aan cash runway op basis van de huidige vrije kasstroom.

Voorspelling contante baan: Er zijn onvoldoende gegevens om te bepalen of XBRANE voldoende cash runway heeft als de vrije kasstroom blijft groeien of krimpen op basis van historische percentages.

Xbrane Biopharma Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Is Xbrane Biopharma (STO:XBRANE) In A Good Position To Deliver On Growth Plans?

We Think Xbrane Biopharma (STO:XBRANE) Needs To Drive Business Growth Carefully

We Think Xbrane Biopharma (STO:XBRANE) Can Afford To Drive Business Growth

Recent updates

Xbrane Biopharma AB (publ) to Report Fiscal Year 2024 Results on Feb 21, 2025

Xbrane Biopharma AB (publ) to Report Fiscal Year 2024 Results on Feb 21, 2025

Even With A 30% Surge, Cautious Investors Are Not Rewarding Xbrane Biopharma AB (publ)'s (STO:XBRANE) Performance Completely

Xbrane Provides Update from Scientific Advice with US FDA on Xdivane™ (Opdivo® Biosimilar Candidate)

Consensus EPS estimates upgraded to kr0.095 loss

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Market Cool On Xbrane Biopharma AB (publ)'s (STO:XBRANE) Revenues Pushing Shares 34% Lower

Market Might Still Lack Some Conviction On Xbrane Biopharma AB (publ) (STO:XBRANE) Even After 32% Share Price Boost

First quarter 2024 earnings: Revenues miss analyst expectations

Xbrane Biopharma AB (publ) to Report Q2, 2024 Results on Aug 28, 2024

Xbrane Biopharma AB (Publ) Appoints Kristoffer Bissessar Was Elected as New Director

Consensus EPS estimates fall by 35%

New minor risk - Financial position

New major risk - Shareholder dilution

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Market cap size

Xbrane Biopharma AB (Publ) Announces Appointment of Nomination Committee

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xbrane Biopharma AB (publ) Focuses on Development Portfolio and Introduces A Cost-Savings Scheme

Xbrane Biopharma AB (publ) to Report First Half, 2024 Results on Jul 17, 2024

Xbrane Biopharma AB (Publ) Presents Nomination Committee

Chief Executive Officer recently sold kr272k worth of stock

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 28%

Forecast breakeven date pushed back to 2025

Xbrane Biopharma AB (publ) to Report Fiscal Year 2023 Results on Mar 27, 2024

Price target increased by 37% to kr219

Consensus revenue estimates increase by 14%, EPS downgraded

Price target increased by 13% to kr253

New major risk - Financial position

Chief Executive Officer recently bought kr150k worth of stock

COO, Head of Biosimilars & Deputy CEO recently bought kr817k worth of stock

Xbrane Biopharma AB (publ) to Report Fiscal Year 2023 Results on Feb 29, 2024

CFO & Head of Investor Relations recently bought kr236k worth of stock

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 15%

Now 22% undervalued

Xbrane Biopharma AB (publ) to Report Q1, 2023 Results on May 04, 2023

Insider recently bought kr156k worth of stock

Chief Executive Officer recently bought kr175k worth of stock

Xbrane Provides an Update on Ranibizumab Biosimilar Candidate FDA Filing

Forecast breakeven date pushed back to 2024

Price target increased to kr173

STADA Arzneimittel AG and Xbrane Biopharma AB Secures EU Approval for Ximluci (Ranibizumab) Biosimilar Referencing Lucentis

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Xbrane Biopharma AB (publ) to Report First Half, 2023 Results on Aug 31, 2023

STADA Arzneimittel AG and Xbrane Biopharma AB (publ) Announce European Medicines Agency’s Committee for Medicinal Products for Human Use Adopts Positive Opinion for Ximluci

Xbrane Biopharma AB (publ), Annual General Meeting, May 04, 2023

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Xbrane Biopharma AB (publ) to Report Q1, 2023 Results on May 31, 2023

Xbrane Biopharma AB (publ) to Report Fiscal Year 2022 Final Results on Mar 31, 2023

Xbrane Provides Update on Ranibizumab Biosimilar Candidate FDA Filing

Chief Executive Officer recently sold kr1.0m worth of stock

An unknown buyer acquired an unknown minority stake in Xbrane Biopharma AB (publ) (OM:XBRANE) from Martin Amark and Siavash Bashiri.

Head of Regulatory Affairs recently bought kr104k worth of stock

Chief Technology Officer recently bought kr699k worth of stock

Is Xbrane Biopharma (STO:XBRANE) In A Good Position To Deliver On Growth Plans?

Xbrane Biopharma AB (publ) Provides Update on Ranibizumab Biosimilar Candidate FDA Filing

Price target increased to kr235

Chief Executive Officer recently sold kr496k worth of stock

Xbrane Biopharma AB (Publ) Announces Positive Top-Line Results from the Pivotal Phase III Equivalence Trial for Xlucane™ - A Biosimilar Candidate to Lucentis

Xbrane Biopharma AB (publ)(OM:XBRANE) dropped from OMX Nordic Small Cap Index

We Think Xbrane Biopharma (STO:XBRANE) Needs To Drive Business Growth Carefully

Consensus EPS estimates increase to -kr9.83

Forecast to breakeven in 2023

Head of Regulatory Affairs recently bought kr125k worth of stock

COO, Head of Biosimilars & Deputy CEO recently bought kr368k worth of stock

Chief Executive Officer recently sold kr172k worth of stock

Market Sentiment Around Loss-Making Xbrane Biopharma AB (publ) (STO:XBRANE)

Xbrane Biopharma AB (publ) Appoints Erik Domines as General Counsel